Chronic Pain Pipeline

DelveInsight’s, “Chronic Pain - Pipeline Insight, 2026” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Chronic Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Chronic Pain: Understanding

Chronic Pain: Overview

Chronic pain is a widespread and debilitating condition that affects over a quarter of the U.S. population, making it one of the most common reasons for outpatient visits. Defined as pain lasting longer than three months, it can severely impair daily functioning and is frequently linked with mental health issues such as depression, anxiety, and an elevated risk of suicide. Managing chronic pain effectively requires a comprehensive approach that includes both pharmacologic and nonpharmacologic strategies. Despite this, inadequate treatment and an overdependence on opioids continue to pose significant challenges, driving up healthcare costs and fueling the ongoing opioid epidemic.

Chronic pain manifests in a variety of forms, including aching, burning, shooting, or electrical sensations, and is often accompanied by symptoms such as fatigue, sleep disturbances, and headaches. Individuals may also experience muscle and joint pain, along with mood-related symptoms like anxiety and depression. Additional signs include gastrointestinal issues like nausea, as well as pain that intensifies with physical activity, particularly in the shoulders, hips, and knees. Radiating pain to the lower extremities, along with tenderness, stiffness, swelling (edema), and joint effusion, are also frequently reported among those suffering from chronic pain. Over time, this ongoing discomfort can interfere with daily activities, reduce mobility, and contribute to social withdrawal and cognitive difficulties, further compounding the individual’s physical and emotional burden.

The pathophysiology of chronic pain involves a multifaceted interplay of mechanisms, including peripheral nerve damage, persistent inflammation, and dysfunctional central pain processing. These changes can lead to heightened sensitivity (hyperalgesia) and pain in response to normally non-painful stimuli (allodynia). Central sensitization, where the nervous system becomes persistently reactive, plays a key role in maintaining chronic pain even after the initial injury has healed. Additionally, changes in neurotransmitter levels, immune system activation, and psychological stress can amplify the pain experience. This complexity highlights the necessity of a holistic treatment approach that considers both physiological and psychosocial components.

Treatment of chronic pain requires a multidisciplinary approach that combines pharmacological and nonpharmacological strategies to achieve effective relief. Medications such as nonopioid analgesics, antidepressants, and anticonvulsants are typically used first, with opioids reserved for cases where other therapies fail, to minimize dependence risks. Nonpharmacological interventions like physical therapy, cognitive behavioral therapy, and acupuncture are essential components in managing both pain and associated psychological issues. For patients with refractory pain, advanced interventional techniques including nerve blocks or spinal cord stimulators may offer additional relief. Timely referral to pain management specialists ensures individualized care and better long-term outcomes.

 

"Chronic Pain- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Pain pipeline landscape is provided which includes the disease overview and Chronic Pain treatment guidelines. The assessment part of the report embraces, in depth Chronic Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Pain R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Pain.

 

Chronic Pain Emerging Drugs Chapters

This segment of the Chronic Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Chronic Pain Emerging Drugs

• AP707: Apurano Pharmaceuticals GmbH

ADEZUNAP (AP707) is manufactured using the patented PuranoTec® manufacturing process so that the cannabinoids (primarily ∆-9-THC) are available as an aqueous nanodispersion. The dispersion is applied sublingually as a mouth spray and the cannabinoids are absorbed quickly and effectively via the oral mucosa. This is possible because the lipophilic, water-insoluble cannabinoids are enclosed in a carrier that is surrounded by a water-soluble shell, the smart coating. As so-called SmartLipids, they remain physically stable in an aqueous environment (no coalescence or agglomerate formation), which ensures passage through the aqueous mukin layer. On the other hand, due to the small particle size of <250 nm, they can enter the bloodstream directly via the oral mucosa. Currently, the drug is in the Phase III stage of its development for the treatment of Chronic Pain.

 

• BRTX 100: BioRestorative Therapies

BRTX‑100 is an innovative autologous mesenchymal stem cell–based therapy designed to treat chronic lumbar and cervical discogenic pain. The process begins with harvesting the patient's own bone marrow, isolating and expanding stem cells under hypoxic conditions, and formulating a biologic secretome enriched with exosomes and growth factors. When administered via a single, minimally invasive intradiscal injection, BRTX‑100 aims to repair degenerative disc tissue and restore disc microenvironment homeostasis. Positioned as a non‑surgical alternative for patients who have not benefited from conservative treatments—such as opioids, injections, or physical therapy—BRTX‑100 offers potential for durable pain relief and functional improvement without the risks associated with surgery or systemic pharmacotherapy. Currently, the drug is in Phase II stage of its development for the treatment of Chronic Pain.

 

• NANTHEIA: ANANDA Scientific

Nantheia™ A1002N5S is an oral cannabidiol (CBD) formulation developed using ANANDA Scientific’s patented Liquid Structure™ delivery technology, which enhances CBD bioavailability, solubility, and stability. Each softgel delivers 50 mg of pharmaceutical-grade CBD designed to provide effective dosing with consistent absorption. Targeting radiculopathic and other forms of chronic non-cancer pain, Nantheia aims to leverage CBD’s anti-inflammatory and analgesic properties to reduce opioid reliance and manage pain through a safer, non-addictive mechanism. Preclinical and early clinical data suggest improved pharmacokinetics and tolerability compared to conventional CBD formulations, offering potential as a well-tolerated therapeutic option in chronic pain management. Currently, the drug is in Phase II stage of its development for the treatment of Chronic Pain.

 

• PIPE-791: Contineum Therapeutics

PIPE‑791 is a potent, brain-penetrant small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1R), designed to address chronic pain associated with osteoarthritis and low back pain. By blocking LPA1R—a key mediator of neuroinflammation, neuronal hyperexcitability, and demyelination—PIPE‑791 is envisioned to modify the central mechanisms contributing to neuropathic pain. With demonstrated target engagement, anti-inflammatory activity, and remyelination potential in preclinical studies, PIPE‑791 offers potential as a non‑opioid therapeutic option that may reduce maladaptive pain signaling and provide durable relief while avoiding systemic opioid-related side effects. Currently, the drug is in Phase I stage of its development for the treatment of Chronic Pain.

Further product details are provided in the report……..

 

Chronic Pain: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Pain drugs segregated based on following parameters that define the scope of the report, such as:

• Major  Players in Chronic Pain
• There are approx. 15+ key companies which are developing the therapies for Chronic Pain. The companies which have their Chronic Pain drug candidates in the most advanced stage, i.e. Phase III include, Apurano Pharmaceuticals GmbH.

 

Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Chronic Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Chronic Pain: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Chronic Pain therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Pain drugs.

 

Chronic Pain Report Insights

• Chronic Pain Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Chronic Pain Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic Pain drugs?
• How many Chronic Pain drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Pain?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Pain therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Pain and their status?
• What are the key designations that have been granted to the emerging drugs?